SlideShare a Scribd company logo
Guidance For Industry
Tablet Scoring: Nomenclature,
Labeling, and Data for Evaluation
with Regulatory Requirement for Other
Regulated Market.
Vivek Singh Rathore
Senior Research Associate
R&D-Formulation
Naari Pharma Pvt. Ltd
vivekosingh_rathore@yahoo.com
9920636295
 INTRODUCTION
 BACKGROUND
 DISCUSSION
1. Guidelines and Criteria
2. Nomenclature and Product Labeling
 AS PER EUROPEAN PHARMACOPEIA
 HEALTH CANADA REQUIREMENT
 QUESTION & ANSWERS FOR SCORING AS PER GUIDANCE
 REFERENCES
TABLE OF CONTENTS
 This guidance provides recommendations to sponsors of new
drug applications (NDAs) and abbreviated new drug
applications (ANDAs) regarding what criteria should be met
when evaluating and labeling tablets that have been
scored.
 Specifically, this guidance recommends:
o Guidelines to follow, data to provide, and criteria to meet
and detail in an application to support approval of a scored
tablet.
o Nomenclature and labeling for approved scored tablets.
This guidance does not address specific finished-product release testing.
I. INTRODUCTION
 A score is a debossed line that runs across the planar surface of the tablet, while
tablet splitting is the practice of breaking or cutting a higher-strength tablet into
smaller portions.
DEFINITION
 Why is it required ?
• When determining whether a generic drug product is the same as the reference
listed drug (RLD), i.e. One characteristic of a tablet dosage form is that it may be
manufactured with a score or scores.(Quality target Product Profile)
• This characteristic is useful because the score can be used to facilitate the splitting
of the tablet into fractions when less than a full tablet is desired for a dose.
• Consistent scoring ensures that the patient is able to adjust the dose, by splitting
the tablet, in the same manner as the RLD. This enables the patient to switch
between products made by different manufacturers without encountering problems
related to the dose.
To be continue……….
Although there are no standards or regulatory requirements that specifically address scoring of tablets
II. BACKGROUND
Quality Target Product Profile (QTPP) is “a prospective summary of the quality
characteristics of a drug product that ideally will be achieved to ensure the
desired quality, taking into account safety and efficacy of the drug product.”
A Critical Quality Attribute (CQA) is “a physical, chemical, biological, or
microbiological property or characteristic that should be within an appropriate
limit, range, or distribution to ensure the desired product quality.”
 The Agency’s concerns ?
• Agency concluded that in some cases, there are possible safety issues, especially when tablets
are not scored or evaluated for splitting.
• Splitting tablet included variations in the
i. Tablet content (Content Uniformity),
ii. Weight (Weight Variation),
iii. Disintegration, or
iv. Dissolution.
which can affect how much drug is present in a split tablet and available for absorption.
In addition, there may be stability issues with splitting tablets.
II. BACKGROUND
 Criteria for functional scoring on solid oral dosage form products to ensure the
quality of both NDA and ANDA scored tablet products can be evaluated and labeled
by:
1) Providing a harmonized approach to chemistry, manufacturing, and controls (CMC)
reviews of scored tablets.
2) Ensuring consistency in nomenclature (e.g., score versus bisect) and labeling.
3) Providing information through product labeling or other means to healthcare
providers.
To be Continue………
III. DISCUSSION
 Below are guidelines and criteria by which a scored tablet’s characteristics will be evaluated as part of
the review process:
1. The dosage amount meant to be achieved after splitting the tablet should not be below the minimum therapeutic dose
indicated on the approved labeling.
2. The split tablet should be safe to handle and not pose risk of unintended drug exposure.
3. Modified release products for which the control of drug release can be compromised by tablet splitting should not
have a scoring feature.
4. The split tablet, when stored in pharmacy dispensing containers (no seal/no desiccant), should demonstrate adequate
stability for a period of 90 days at 25º C, plus or minus 2º C/60 percent Relative Humidity (RH), plus or minus 5
percent RH.
5. The split tablet portions should meet the same finished-product testing requirements as for a whole-tablet product
with equivalent strength. A risk assessment should be provided to justify the tests and criteria for product with the
proposed functional scoring. The resulting data should be provided to the Agency for evaluation. The assessment
should be undertaken on both tablets that are split nonmechanically (by hand) and tablets that are split
mechanically (with a tablet splitter). Any recommended dissolution test data must be generated on a minimum of 12
individual split tablet portions.
To be Continue………
III. A. Guidelines and Criteria
Split Nonmechanically (by hand) Split Mechanically (with a tablet splitter)
5. Below are typical criteria:
Criteria 5. a. Immediate Release Solid Oral Dosage
Forms
5. b. Modified Release Solid
Oral Dosage Forms (Using
Matrix Technology)
5. c. Modified Release Solid Oral
Dosage Forms (Using
Compressed Film Coated
Components)
USP General Chapter <905>
Uniformity of Dosage Units
Here each split portion of a whole tablet is considered
a unit of dose and should meet the uniformity of
dosage unit requirement.
Testing for Weight Variation is permitted for split tablet
portions intended to contain 25 mg or more of a drug
substance that comprises 25 percent or more (by weight)
of the split tablet portion. Otherwise, the test for
Content Uniformity should be used.
All criteria same as under section
III.A.5.a should be met.
All above criteria under sections
III.A.5.a and III.A.5.b should be met.
Tablet splitability at both ends
of the proposed hardness
range should be demonstrated
by [Tablets split
nonmechanically (by hand) and
split mechanically (with a
tablet splitter)]
1. Testing 15 tablets to ensure a loss of mass of less than
3.0 percent between the individual segments (30 for
bisected tablets, 45 for trisected tablets, etc.) when
compared to the whole tablet. The resulting data for
each tablet should be provided to the Agency for
evaluation.
2. Confirming that the split tablet portions meet the USP
Friability requirement (NMT 1%w/w)
All criteria same as under section
III.A.5.a should be met.
All above criteria under sections
III.A.5.a and III.A.5.b should be met.
Dissolution Dissolution data on split tablet portions should meet
finished-product release requirements.
1. Dissolution should be
demonstrated at both ends of
the hardness range.
2. Dissolution on whole versus
split tablet portions should
meet the similarity factor (f2)
criteria.
Dissolution profile on pre-compressed
beads versus post-compressed whole
and split tablet portions should meet
similarity factor (f2) criteria to
ascertain the integrity of beads during
compression.
III. A. Guidelines and Criteria
TABLET SCORING for US mkt by Vivek Singh Rathore
Test as per Guidance Low Hardness Optimum Hardness High Hardness
Tablet Splitability
(Testing of 15 tablets to ensure a Loss of Mass (LoM) should NMT
3% b/w individual segement. When compared to whole tablet.
Tablet Weight (mg) Tablet Weight (mg) Tablet Weight (mg)
Whole Tab LHS RHS LoM (%) Whole Tab LHS RHS LoM (%) Whole Tab LHS RHS LoM(%)
200 98 99 1.5
Friability
(of split tablet portion should NMT 1.0%)
Whole Tab (%w/w) LHS (%w/w) RHS (%w/w) Whole Tab (%w/w) LHS (%w/w) RHS (%w/w) Whole Tab (%w/w) LHS (%w/w) RHS (%w/w)
Uniformity of Dosage Unit
Content Uniformity (CU)
Optimum Hardness
Whole Tab LHS RHS
Tab 1 to Tab 10
Average
Minimum
Maximum
%RSD
AV Value
Dissolution
(Dissolution data on split tablet portions should meet finished-
product release)
Release Medium: 0.02% SLS in 0.1N HCL, 900ml, 100rpm, USP-I (Paddle) - Q Value NLT 70% in 60 Min (For e.g)
Batch no.
XYZ
Whole Tab LHS RHS
Time Points (min) % Rel % RSD % Rel % RSD % Rel % RSD
10
15
20
30
45
Recovery
6. Scoring configuration of generic drug products should be the same as the
RLD.
 Where the scoring configuration is protected by patent, contact the Office of Generic
Drugs for guidance.
 For scoring configurations proposed for abbreviated applications that were accepted
through the suitability petition process, contact the Office of Generic Drugs for
guidance.
7. An evaluation of the tablet splitability should be provided during the
postapproval period for any product changes at Level 2 and Level 3 as
defined in the Agency’s Scale-up and Post-Approval Changes (SUPAC)
guidances.
III. A. Guidelines and Criteria
 New products that meet the above-referenced criteria can be labeled as having functional
scoring. Such labeling should appear in all of the following sections of the prescribing
information
 “Dosage Forms and Strength” section of the Highlights.
 “Dosage Forms and Strength” section of the Full Prescribing Information.
 “How Supplied” section of the Full Prescribing Information.
 For currently marketed products: manufacturers have the option to perform such an
assessment and provide data for evaluation to the drug product application. Product
labeling should be updated to state that it has functional scoring.
 Functional scoring used in the labeling can communicate to healthcare providers that the
product has been evaluated against the established criteria.
III. B. Nomenclature and Product Labeling
SUBDIVISION OF TABLETS
Why Required?
1.To ease the intake of the medicinal product.
2. To comply with the posology.
3. To ensure that patient will receive the intended dose.
Efficacy of breakmark must be assessed during development of product,
in respect of uniformity of mass of the subdivided part:
Take 30 tablet at random, break them by hand take 1 part for the test & reject
the other part.
Weigh each of 30 parts individually & calculate the average mass.
The tablet comply with the test if NMT 1 individual mass is outside the limit of
85% to 115% of the average mass.
The tablet fail to comply with the test if more than 1 individual mass is outside
the limit of 75% to 125% of the average mass
As per European Pharmacopeia (EP)
 Same as for “US-FDA Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data
for Evaluation”
 Refer to “Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and
Abbreviated New Drug Submissions (ANDSs), Page no. 46 – 47”
HEALTH CANADA REQUIREMENT
Reference: ANDA Submissions – Refuse-to-Receive Standards: Questions and Answers
Guidance for Industry. DRAFT GUIDANCE , October 2017 , Page no. 17
Reference: Guidance for Industry ANDAs: Stability Testing of Drug Substances and
Products, Questions and Answers, May 2014 , Page no. 15
QUESTION & ANSWERS FOR SCORING AS PER GUIDANCE
1. Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for
Evaluation, March 2013, Page no. 1 - 5
2. Quality by Design for ANDAs: An Example for Immediate-Release Dosage
Forms, Page no. 10 - 11
3. Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions
(NDSs) and Abbreviated New Drug Submissions (ANDSs), Page no. 46 – 47
4. Guidance for Industry ANDAs: Stability Testing of Drug Substances and
Products, Questions and Answers, May 2014 , Page no. 15
5. ANDA Submissions – Refuse-to-Receive Standards: Questions and Answers
Guidance for Industry. DRAFT GUIDANCE , October 2017 , Page no. 17
REFERENCES
Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market.
Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market.

More Related Content

What's hot

In process & finished products quality control test of capsule
In process & finished products quality control test of capsuleIn process & finished products quality control test of capsule
In process & finished products quality control test of capsule
ArpitSuralkar
 
Marketing authorization
Marketing authorizationMarketing authorization
Marketing authorization
santoshnarla
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
bdvfgbdhg
 
GUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTINGGUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTING
Sagar Savale
 
Bracketing and Matrixing Methods for Stability analysis
Bracketing and Matrixing Methods for Stability analysisBracketing and Matrixing Methods for Stability analysis
Bracketing and Matrixing Methods for Stability analysis
Sarath Chandra
 
Regulatory requirements of row countries
Regulatory requirements of row countriesRegulatory requirements of row countries
Regulatory requirements of row countries
Divya Pushp
 
ICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra MohanICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra Mohan
Chandra Mohan
 
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
MedicReS
 
Regulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi ArabiaRegulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi Arabia
Sridhar S
 
Size shape and other physical attributes guidance FDA.pptx
Size shape and other physical attributes guidance FDA.pptxSize shape and other physical attributes guidance FDA.pptx
Size shape and other physical attributes guidance FDA.pptx
Vikram Jeet Singh
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
inemet
 
ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10
BHAGYASHRI BHANAGE
 
Product Lifecycle Management Part 1 - ICHQ12.pptx
Product Lifecycle Management Part 1 - ICHQ12.pptxProduct Lifecycle Management Part 1 - ICHQ12.pptx
Product Lifecycle Management Part 1 - ICHQ12.pptx
GxPProfessional
 
Quality Control Test
Quality Control TestQuality Control Test
Quality Control Test
TalhaAfzal13
 
Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.
GMP EDUCATION : Not for Profit Organization
 
EU Variations & Renewals
EU Variations & RenewalsEU Variations & Renewals
EU Variations & Renewals
Sachin Chede
 
PROCESS VALIDATION OF INJECTABLES
PROCESS VALIDATION OF INJECTABLESPROCESS VALIDATION OF INJECTABLES
PROCESS VALIDATION OF INJECTABLES
Khushboo Pasbola
 
Fluid bed processor, gpcg
Fluid bed processor, gpcgFluid bed processor, gpcg
Fluid bed processor, gpcg
Prashant Patil
 
Stability study of Pharmaceutical Products and Regulatory Requirements
Stability study of Pharmaceutical Products and Regulatory Requirements Stability study of Pharmaceutical Products and Regulatory Requirements
Stability study of Pharmaceutical Products and Regulatory Requirements
Md. Zakaria Faruki
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient Compatibility
Suraj Choudhary
 

What's hot (20)

In process & finished products quality control test of capsule
In process & finished products quality control test of capsuleIn process & finished products quality control test of capsule
In process & finished products quality control test of capsule
 
Marketing authorization
Marketing authorizationMarketing authorization
Marketing authorization
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
 
GUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTINGGUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTING
 
Bracketing and Matrixing Methods for Stability analysis
Bracketing and Matrixing Methods for Stability analysisBracketing and Matrixing Methods for Stability analysis
Bracketing and Matrixing Methods for Stability analysis
 
Regulatory requirements of row countries
Regulatory requirements of row countriesRegulatory requirements of row countries
Regulatory requirements of row countries
 
ICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra MohanICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra Mohan
 
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
 
Regulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi ArabiaRegulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi Arabia
 
Size shape and other physical attributes guidance FDA.pptx
Size shape and other physical attributes guidance FDA.pptxSize shape and other physical attributes guidance FDA.pptx
Size shape and other physical attributes guidance FDA.pptx
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
 
ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10
 
Product Lifecycle Management Part 1 - ICHQ12.pptx
Product Lifecycle Management Part 1 - ICHQ12.pptxProduct Lifecycle Management Part 1 - ICHQ12.pptx
Product Lifecycle Management Part 1 - ICHQ12.pptx
 
Quality Control Test
Quality Control TestQuality Control Test
Quality Control Test
 
Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.
 
EU Variations & Renewals
EU Variations & RenewalsEU Variations & Renewals
EU Variations & Renewals
 
PROCESS VALIDATION OF INJECTABLES
PROCESS VALIDATION OF INJECTABLESPROCESS VALIDATION OF INJECTABLES
PROCESS VALIDATION OF INJECTABLES
 
Fluid bed processor, gpcg
Fluid bed processor, gpcgFluid bed processor, gpcg
Fluid bed processor, gpcg
 
Stability study of Pharmaceutical Products and Regulatory Requirements
Stability study of Pharmaceutical Products and Regulatory Requirements Stability study of Pharmaceutical Products and Regulatory Requirements
Stability study of Pharmaceutical Products and Regulatory Requirements
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient Compatibility
 

Similar to Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market.

IPQC and FPQC for tablets
IPQC and FPQC for tabletsIPQC and FPQC for tablets
IPQC and FPQC for tablets
Mukesh Patil
 
Introduction to quality control of diffferent dosage forms.pptx
Introduction to quality control of diffferent dosage forms.pptxIntroduction to quality control of diffferent dosage forms.pptx
Introduction to quality control of diffferent dosage forms.pptx
bojiacaalii
 
Qualityassurancecontrolinpharmaindustry
QualityassurancecontrolinpharmaindustryQualityassurancecontrolinpharmaindustry
Qualityassurancecontrolinpharmaindustry
Malla Reddy College of Pharmacy
 
4
44
Q6 guidelines
Q6 guidelinesQ6 guidelines
Q6 guidelines
Anjali Aji
 
ICH Q8 Guidelines
ICH Q8 GuidelinesICH Q8 Guidelines
ICH Q8 Guidelines
MANIKANDAN V
 
Supac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage FormSupac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage Form
Jubiliant Generics Limited
 
Supac
SupacSupac
Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)
Pradeep Kumar
 
stability ASEAN guidelines
stability ASEAN guidelinesstability ASEAN guidelines
stability ASEAN guidelines
HERNINTA PRAMITASARI
 
CMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etcCMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etc
JayeshRajput7
 
Regulatory affairs cmc , post approval regulatory affairs
Regulatory affairs   cmc , post approval regulatory affairsRegulatory affairs   cmc , post approval regulatory affairs
Regulatory affairs cmc , post approval regulatory affairs
ArjunDhawale
 
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
MukeshKumarBhagat
 
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptxICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
Trishala Bhatt
 
In process & finished products quality control test for pharmaceuticals
In process & finished products quality control test for pharmaceuticalsIn process & finished products quality control test for pharmaceuticals
In process & finished products quality control test for pharmaceuticals
Suraj Ghorpade
 
STABILITY STUDIES OF PHARMACEUTICALS.pdf
STABILITY STUDIES OF PHARMACEUTICALS.pdfSTABILITY STUDIES OF PHARMACEUTICALS.pdf
STABILITY STUDIES OF PHARMACEUTICALS.pdf
BALASUNDARESAN M
 
Supac
SupacSupac
Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in Pharmaceuticals
Pharmaguideline
 
Regulatory Overview
Regulatory OverviewRegulatory Overview
Regulatory Overview
Rohit Thanage
 
Comparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with otherComparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with other
Jun Brown
 

Similar to Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market. (20)

IPQC and FPQC for tablets
IPQC and FPQC for tabletsIPQC and FPQC for tablets
IPQC and FPQC for tablets
 
Introduction to quality control of diffferent dosage forms.pptx
Introduction to quality control of diffferent dosage forms.pptxIntroduction to quality control of diffferent dosage forms.pptx
Introduction to quality control of diffferent dosage forms.pptx
 
Qualityassurancecontrolinpharmaindustry
QualityassurancecontrolinpharmaindustryQualityassurancecontrolinpharmaindustry
Qualityassurancecontrolinpharmaindustry
 
4
44
4
 
Q6 guidelines
Q6 guidelinesQ6 guidelines
Q6 guidelines
 
ICH Q8 Guidelines
ICH Q8 GuidelinesICH Q8 Guidelines
ICH Q8 Guidelines
 
Supac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage FormSupac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage Form
 
Supac
SupacSupac
Supac
 
Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)
 
stability ASEAN guidelines
stability ASEAN guidelinesstability ASEAN guidelines
stability ASEAN guidelines
 
CMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etcCMC, post approval regulatory affairs, etc
CMC, post approval regulatory affairs, etc
 
Regulatory affairs cmc , post approval regulatory affairs
Regulatory affairs   cmc , post approval regulatory affairsRegulatory affairs   cmc , post approval regulatory affairs
Regulatory affairs cmc , post approval regulatory affairs
 
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...
 
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptxICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptx
 
In process & finished products quality control test for pharmaceuticals
In process & finished products quality control test for pharmaceuticalsIn process & finished products quality control test for pharmaceuticals
In process & finished products quality control test for pharmaceuticals
 
STABILITY STUDIES OF PHARMACEUTICALS.pdf
STABILITY STUDIES OF PHARMACEUTICALS.pdfSTABILITY STUDIES OF PHARMACEUTICALS.pdf
STABILITY STUDIES OF PHARMACEUTICALS.pdf
 
Supac
SupacSupac
Supac
 
Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in Pharmaceuticals
 
Regulatory Overview
Regulatory OverviewRegulatory Overview
Regulatory Overview
 
Comparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with otherComparison of stability testing requirements of ich with other
Comparison of stability testing requirements of ich with other
 

Recently uploaded

Top 10 Antibiotic Manufacturers in India
Top 10 Antibiotic Manufacturers in IndiaTop 10 Antibiotic Manufacturers in India
Top 10 Antibiotic Manufacturers in India
DM Pharma
 
ALTERNATIVE THERAPIES DURING LABOUR.pptx
ALTERNATIVE THERAPIES DURING LABOUR.pptxALTERNATIVE THERAPIES DURING LABOUR.pptx
ALTERNATIVE THERAPIES DURING LABOUR.pptx
BhagyashreeDash6
 
Asthma CPD.pptx.Based on new GINA guidelines
Asthma CPD.pptx.Based on new GINA guidelinesAsthma CPD.pptx.Based on new GINA guidelines
Asthma CPD.pptx.Based on new GINA guidelines
RanaTareq1
 
chapter 1- changing trends in physical education.pptx
chapter 1- changing trends in physical education.pptxchapter 1- changing trends in physical education.pptx
chapter 1- changing trends in physical education.pptx
divijsinghrenu10
 
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in CityGirls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
snehamittal#G05
 
Acute complications of sickle cell disease .pdf
Acute complications of sickle cell disease .pdfAcute complications of sickle cell disease .pdf
Acute complications of sickle cell disease .pdf
RawanAlakwaa
 
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in CityGirls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
snehamittal#G05
 
How dental support group work...........
How dental support group work...........How dental support group work...........
How dental support group work...........
AvilasDentalGroup
 
Ihuman Case Study Help-ihuman case study modules help.pdf
Ihuman Case Study Help-ihuman case study modules help.pdfIhuman Case Study Help-ihuman case study modules help.pdf
Ihuman Case Study Help-ihuman case study modules help.pdf
Reliable Assignments Help
 
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
jealousviolet
 
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
BinduBandheBarman
 
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
stanslausnzuki569
 
nhs fpx 4000 assessment 2 applying research skills.pdf
nhs fpx 4000 assessment 2 applying research skills.pdfnhs fpx 4000 assessment 2 applying research skills.pdf
nhs fpx 4000 assessment 2 applying research skills.pdf
aleyna0069
 
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
saroni night girls
 
ppt on National health mission copy - pptx
ppt on National health mission copy - pptxppt on National health mission copy - pptx
ppt on National health mission copy - pptx
AbinanthanLekhashree
 
arm balance asana - Comprehensive understanding of arm balancing asana
arm balance asana - Comprehensive understanding of arm balancing asanaarm balance asana - Comprehensive understanding of arm balancing asana
arm balance asana - Comprehensive understanding of arm balancing asana
Karuna Yoga Vidya Peetham
 
heart intro.pptx full introduction about the heart
heart intro.pptx full introduction about the heartheart intro.pptx full introduction about the heart
heart intro.pptx full introduction about the heart
krithikamugunthavel
 
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor DrugsDrugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
sanjayudps2016
 
Bronchiectasis and Physiotherapy Management
Bronchiectasis and Physiotherapy ManagementBronchiectasis and Physiotherapy Management
Bronchiectasis and Physiotherapy Management
abdulazeezvpadikkal
 
Respectful Care _Special Patient Care for health science students
Respectful Care _Special Patient Care for health science studentsRespectful Care _Special Patient Care for health science students
Respectful Care _Special Patient Care for health science students
Debre Berhan University
 

Recently uploaded (20)

Top 10 Antibiotic Manufacturers in India
Top 10 Antibiotic Manufacturers in IndiaTop 10 Antibiotic Manufacturers in India
Top 10 Antibiotic Manufacturers in India
 
ALTERNATIVE THERAPIES DURING LABOUR.pptx
ALTERNATIVE THERAPIES DURING LABOUR.pptxALTERNATIVE THERAPIES DURING LABOUR.pptx
ALTERNATIVE THERAPIES DURING LABOUR.pptx
 
Asthma CPD.pptx.Based on new GINA guidelines
Asthma CPD.pptx.Based on new GINA guidelinesAsthma CPD.pptx.Based on new GINA guidelines
Asthma CPD.pptx.Based on new GINA guidelines
 
chapter 1- changing trends in physical education.pptx
chapter 1- changing trends in physical education.pptxchapter 1- changing trends in physical education.pptx
chapter 1- changing trends in physical education.pptx
 
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in CityGirls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Mumbai 000XX00000 Provide Best And Top Girl Service And No1 in City
 
Acute complications of sickle cell disease .pdf
Acute complications of sickle cell disease .pdfAcute complications of sickle cell disease .pdf
Acute complications of sickle cell disease .pdf
 
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in CityGirls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
Girls Call Thane 000XX00000 Provide Best And Top Girl Service And No1 in City
 
How dental support group work...........
How dental support group work...........How dental support group work...........
How dental support group work...........
 
Ihuman Case Study Help-ihuman case study modules help.pdf
Ihuman Case Study Help-ihuman case study modules help.pdfIhuman Case Study Help-ihuman case study modules help.pdf
Ihuman Case Study Help-ihuman case study modules help.pdf
 
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
High Class Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And...
 
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
RTI STD TORCH UTI ,HIV/AIDS BY BINDU PRE.
 
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
TEST BANK & Solutions Manual For Medical Assisting Administrative & Clinical ...
 
nhs fpx 4000 assessment 2 applying research skills.pdf
nhs fpx 4000 assessment 2 applying research skills.pdfnhs fpx 4000 assessment 2 applying research skills.pdf
nhs fpx 4000 assessment 2 applying research skills.pdf
 
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
Premium Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No...
 
ppt on National health mission copy - pptx
ppt on National health mission copy - pptxppt on National health mission copy - pptx
ppt on National health mission copy - pptx
 
arm balance asana - Comprehensive understanding of arm balancing asana
arm balance asana - Comprehensive understanding of arm balancing asanaarm balance asana - Comprehensive understanding of arm balancing asana
arm balance asana - Comprehensive understanding of arm balancing asana
 
heart intro.pptx full introduction about the heart
heart intro.pptx full introduction about the heartheart intro.pptx full introduction about the heart
heart intro.pptx full introduction about the heart
 
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor DrugsDrugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
Drugs Used for the Hyperlipidemic drugs, HMG-CoA Reductase Inhibitor Drugs
 
Bronchiectasis and Physiotherapy Management
Bronchiectasis and Physiotherapy ManagementBronchiectasis and Physiotherapy Management
Bronchiectasis and Physiotherapy Management
 
Respectful Care _Special Patient Care for health science students
Respectful Care _Special Patient Care for health science studentsRespectful Care _Special Patient Care for health science students
Respectful Care _Special Patient Care for health science students
 

Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market.

  • 1. Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation with Regulatory Requirement for Other Regulated Market. Vivek Singh Rathore Senior Research Associate R&D-Formulation Naari Pharma Pvt. Ltd vivekosingh_rathore@yahoo.com 9920636295
  • 2.  INTRODUCTION  BACKGROUND  DISCUSSION 1. Guidelines and Criteria 2. Nomenclature and Product Labeling  AS PER EUROPEAN PHARMACOPEIA  HEALTH CANADA REQUIREMENT  QUESTION & ANSWERS FOR SCORING AS PER GUIDANCE  REFERENCES TABLE OF CONTENTS
  • 3.  This guidance provides recommendations to sponsors of new drug applications (NDAs) and abbreviated new drug applications (ANDAs) regarding what criteria should be met when evaluating and labeling tablets that have been scored.  Specifically, this guidance recommends: o Guidelines to follow, data to provide, and criteria to meet and detail in an application to support approval of a scored tablet. o Nomenclature and labeling for approved scored tablets. This guidance does not address specific finished-product release testing. I. INTRODUCTION
  • 4.  A score is a debossed line that runs across the planar surface of the tablet, while tablet splitting is the practice of breaking or cutting a higher-strength tablet into smaller portions. DEFINITION
  • 5.  Why is it required ? • When determining whether a generic drug product is the same as the reference listed drug (RLD), i.e. One characteristic of a tablet dosage form is that it may be manufactured with a score or scores.(Quality target Product Profile) • This characteristic is useful because the score can be used to facilitate the splitting of the tablet into fractions when less than a full tablet is desired for a dose. • Consistent scoring ensures that the patient is able to adjust the dose, by splitting the tablet, in the same manner as the RLD. This enables the patient to switch between products made by different manufacturers without encountering problems related to the dose. To be continue………. Although there are no standards or regulatory requirements that specifically address scoring of tablets II. BACKGROUND
  • 6. Quality Target Product Profile (QTPP) is “a prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product.” A Critical Quality Attribute (CQA) is “a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.”
  • 7.  The Agency’s concerns ? • Agency concluded that in some cases, there are possible safety issues, especially when tablets are not scored or evaluated for splitting. • Splitting tablet included variations in the i. Tablet content (Content Uniformity), ii. Weight (Weight Variation), iii. Disintegration, or iv. Dissolution. which can affect how much drug is present in a split tablet and available for absorption. In addition, there may be stability issues with splitting tablets. II. BACKGROUND
  • 8.  Criteria for functional scoring on solid oral dosage form products to ensure the quality of both NDA and ANDA scored tablet products can be evaluated and labeled by: 1) Providing a harmonized approach to chemistry, manufacturing, and controls (CMC) reviews of scored tablets. 2) Ensuring consistency in nomenclature (e.g., score versus bisect) and labeling. 3) Providing information through product labeling or other means to healthcare providers. To be Continue……… III. DISCUSSION
  • 9.  Below are guidelines and criteria by which a scored tablet’s characteristics will be evaluated as part of the review process: 1. The dosage amount meant to be achieved after splitting the tablet should not be below the minimum therapeutic dose indicated on the approved labeling. 2. The split tablet should be safe to handle and not pose risk of unintended drug exposure. 3. Modified release products for which the control of drug release can be compromised by tablet splitting should not have a scoring feature. 4. The split tablet, when stored in pharmacy dispensing containers (no seal/no desiccant), should demonstrate adequate stability for a period of 90 days at 25º C, plus or minus 2º C/60 percent Relative Humidity (RH), plus or minus 5 percent RH. 5. The split tablet portions should meet the same finished-product testing requirements as for a whole-tablet product with equivalent strength. A risk assessment should be provided to justify the tests and criteria for product with the proposed functional scoring. The resulting data should be provided to the Agency for evaluation. The assessment should be undertaken on both tablets that are split nonmechanically (by hand) and tablets that are split mechanically (with a tablet splitter). Any recommended dissolution test data must be generated on a minimum of 12 individual split tablet portions. To be Continue……… III. A. Guidelines and Criteria
  • 10. Split Nonmechanically (by hand) Split Mechanically (with a tablet splitter)
  • 11. 5. Below are typical criteria: Criteria 5. a. Immediate Release Solid Oral Dosage Forms 5. b. Modified Release Solid Oral Dosage Forms (Using Matrix Technology) 5. c. Modified Release Solid Oral Dosage Forms (Using Compressed Film Coated Components) USP General Chapter <905> Uniformity of Dosage Units Here each split portion of a whole tablet is considered a unit of dose and should meet the uniformity of dosage unit requirement. Testing for Weight Variation is permitted for split tablet portions intended to contain 25 mg or more of a drug substance that comprises 25 percent or more (by weight) of the split tablet portion. Otherwise, the test for Content Uniformity should be used. All criteria same as under section III.A.5.a should be met. All above criteria under sections III.A.5.a and III.A.5.b should be met. Tablet splitability at both ends of the proposed hardness range should be demonstrated by [Tablets split nonmechanically (by hand) and split mechanically (with a tablet splitter)] 1. Testing 15 tablets to ensure a loss of mass of less than 3.0 percent between the individual segments (30 for bisected tablets, 45 for trisected tablets, etc.) when compared to the whole tablet. The resulting data for each tablet should be provided to the Agency for evaluation. 2. Confirming that the split tablet portions meet the USP Friability requirement (NMT 1%w/w) All criteria same as under section III.A.5.a should be met. All above criteria under sections III.A.5.a and III.A.5.b should be met. Dissolution Dissolution data on split tablet portions should meet finished-product release requirements. 1. Dissolution should be demonstrated at both ends of the hardness range. 2. Dissolution on whole versus split tablet portions should meet the similarity factor (f2) criteria. Dissolution profile on pre-compressed beads versus post-compressed whole and split tablet portions should meet similarity factor (f2) criteria to ascertain the integrity of beads during compression. III. A. Guidelines and Criteria
  • 12. TABLET SCORING for US mkt by Vivek Singh Rathore Test as per Guidance Low Hardness Optimum Hardness High Hardness Tablet Splitability (Testing of 15 tablets to ensure a Loss of Mass (LoM) should NMT 3% b/w individual segement. When compared to whole tablet. Tablet Weight (mg) Tablet Weight (mg) Tablet Weight (mg) Whole Tab LHS RHS LoM (%) Whole Tab LHS RHS LoM (%) Whole Tab LHS RHS LoM(%) 200 98 99 1.5 Friability (of split tablet portion should NMT 1.0%) Whole Tab (%w/w) LHS (%w/w) RHS (%w/w) Whole Tab (%w/w) LHS (%w/w) RHS (%w/w) Whole Tab (%w/w) LHS (%w/w) RHS (%w/w) Uniformity of Dosage Unit Content Uniformity (CU) Optimum Hardness Whole Tab LHS RHS Tab 1 to Tab 10 Average Minimum Maximum %RSD AV Value Dissolution (Dissolution data on split tablet portions should meet finished- product release) Release Medium: 0.02% SLS in 0.1N HCL, 900ml, 100rpm, USP-I (Paddle) - Q Value NLT 70% in 60 Min (For e.g) Batch no. XYZ Whole Tab LHS RHS Time Points (min) % Rel % RSD % Rel % RSD % Rel % RSD 10 15 20 30 45 Recovery
  • 13. 6. Scoring configuration of generic drug products should be the same as the RLD.  Where the scoring configuration is protected by patent, contact the Office of Generic Drugs for guidance.  For scoring configurations proposed for abbreviated applications that were accepted through the suitability petition process, contact the Office of Generic Drugs for guidance. 7. An evaluation of the tablet splitability should be provided during the postapproval period for any product changes at Level 2 and Level 3 as defined in the Agency’s Scale-up and Post-Approval Changes (SUPAC) guidances. III. A. Guidelines and Criteria
  • 14.  New products that meet the above-referenced criteria can be labeled as having functional scoring. Such labeling should appear in all of the following sections of the prescribing information  “Dosage Forms and Strength” section of the Highlights.  “Dosage Forms and Strength” section of the Full Prescribing Information.  “How Supplied” section of the Full Prescribing Information.  For currently marketed products: manufacturers have the option to perform such an assessment and provide data for evaluation to the drug product application. Product labeling should be updated to state that it has functional scoring.  Functional scoring used in the labeling can communicate to healthcare providers that the product has been evaluated against the established criteria. III. B. Nomenclature and Product Labeling
  • 15. SUBDIVISION OF TABLETS Why Required? 1.To ease the intake of the medicinal product. 2. To comply with the posology. 3. To ensure that patient will receive the intended dose. Efficacy of breakmark must be assessed during development of product, in respect of uniformity of mass of the subdivided part: Take 30 tablet at random, break them by hand take 1 part for the test & reject the other part. Weigh each of 30 parts individually & calculate the average mass. The tablet comply with the test if NMT 1 individual mass is outside the limit of 85% to 115% of the average mass. The tablet fail to comply with the test if more than 1 individual mass is outside the limit of 75% to 125% of the average mass As per European Pharmacopeia (EP)
  • 16.  Same as for “US-FDA Guidance For Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation”  Refer to “Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs), Page no. 46 – 47” HEALTH CANADA REQUIREMENT
  • 17. Reference: ANDA Submissions – Refuse-to-Receive Standards: Questions and Answers Guidance for Industry. DRAFT GUIDANCE , October 2017 , Page no. 17 Reference: Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers, May 2014 , Page no. 15 QUESTION & ANSWERS FOR SCORING AS PER GUIDANCE
  • 18. 1. Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation, March 2013, Page no. 1 - 5 2. Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms, Page no. 10 - 11 3. Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs), Page no. 46 – 47 4. Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers, May 2014 , Page no. 15 5. ANDA Submissions – Refuse-to-Receive Standards: Questions and Answers Guidance for Industry. DRAFT GUIDANCE , October 2017 , Page no. 17 REFERENCES